Bemcentinib prevents AXL phosphorylation and downstream signaling in preclinical models of AML, resulting in reduced tumor growth, enhanced sensitivity towards therapy and enhanced anti-leukemic immune responses19,25,28. The gene discussed is AXL; the disease is neoplasm.